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Sirolimus, an inhibitor of the mammalian target of rapamycin 
(mTOR), is used as an immunosuppressant for solid-organ transplant 
recipients and patients with autoimmune disorders. We report a case 
of lymphoedema, a rare complication of sirolimus, and discuss the 
mechanism of drug action, the adverse effects and the challenges 
of treating a kidney transplant recipient with this complication in a 
resource-limited environment.
Case report
A 42-year-old black South African (SA) man received a cadaveric 
kidney transplant for end-stage renal disease secondary to type  1 
diabetes mellitus. Before the transplant, he had been receiving 
haemodialysis via a left brachiocephalic arteriovenous fistula for 
3 years and peritoneal dialysis for 2 years before that.
After the transplant, the patient received basiliximab, methyl-
prednisolone and byclosporine for induction immune suppression and 
then triple therapy with cyclosporine, prednisone and myclophenolate 
mofetil (MMF) for maintenance immune suppression. In August 
2009, he developed biopsy-proven mild calcineurin renal toxicity, and 
the cyclosporine was replaced with sirolimus. The mean sirolimus 
dose was 2 mg daily, with blood trough levels ranging between 3.8 
and 11.3 ng/mL (mean 4.5, therapeutic range 4 - 11).
The patient first complained of progressive painful bilateral lower 
limb swelling, the left leg being more affected than the right, in 
September 2010, 13 months after the initiation of sirolimus. Despite 
the graft being in the right iliac fossa and multiple previous central 
venous catheterisations of both femoral veins, Doppler ultrasound 
assessments excluded a venous cause for the leg swelling. Graft 
function remained stable, with a mean creatinine level of 125 µg/
mL. Lymphangiography showed almost complete obstruction of the 
deep lymphatic system of the lower limbs with back-diffusion into 
the peripheral superficial lymphatic system, the left leg more affected 
than the right.
In the absence of a significant family history and other causes for 
lymphatic obstruction, the patient was diagnosed with sirolimus-
induced lymphoedema. Initially the treatment was continued because 
he had excellent graft function despite the physical disfigurement. 
Low-dose loop diuretics did not result in any notable improvement.
The lymphoedema worsened, and sirolimus treatment was stopped 
in April 2015 when the patient was unable to cope with the pain and 
the disfigurement impacted on his quality of life. He is currently 
receiving tacrolimus, MMF and prednisone for immune suppression, 
and his graph function has remained stable. There has been slight 
improvement in the lymphoedema with physiotherapy and cone 
compression bandaging.
Discussion
The prevalence of chronic kidney disease (CKD) has increased 
significantly over recent decades. It is currently estimated to be 
6 - 18% worldwide.[1] The burden of disease is highest in low-
income settings such as sub-Saharan Africa, where the incidence 
is estimated to be three to four times higher than in developed 
countries.[2] In SA, there was a 67% increase in deaths due to CKD 
from 1999 to 2006.[3] In the black African population, malignant 
hypertension is the most common cause, followed by diabetes 
mellitus and glomerulonephropathies. [4] Part of the challenge in 
managing CKD is late presentation of patients, a lack of adequate 
screening programmes and risk factor control, and the high cost of 
renal replacement therapy.
Organ transplantation is the treatment of choice for end-stage 
renal failure, but it carries a high burden of cost to both the patient 
and the healthcare system because patients require lifelong immune 
suppression to prevent acute and chronic rejection.
Sirolimus (also known as rapamycin) is a macrocylic lactone 
immunosuppressive agent produced by Streptomyces hygroscopicus. 
It inhibits T-lymphocyte activation and proliferation due to antigen 
and cytokine stimulation, and reduces antibody production. It binds 
to the immunophilin FK binding protein-12 (FKBP-12) and forms an 
immunosuppressive complex within the cell. The sirolimus/FKBP-12 
complex binds to and inhibits activation of the regulatory kinase, 
the mammalian target of rapamycin (mTOR), thus inhibiting the 
progression from G1 to the S phase of the cell cycle.
Sirolimus is currently used in patients with organ transplants 
and some autoimmune diseases. As with other immunosuppressive 
agents, adverse effects such as a predisposition to infections, cyto-
penias and poor wound healing may limit its use. However, compared 
with calcineurin inhibitors, it is associated with lower rates of 
nephrotoxicity, hypertension and malignancy, all of which have an 
impact on long-term graft function. The most common side-effects 
of sirolimus are dyslipidaemia, anaemia, arthralgia, gastrointestinal 
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disturbances, skin abnormalities, stomatitis, electrolyte abnormalities, 
pneumonitis and peripheral oedema.[5]
Patients with lymphatic obstruction can present with lymphoceles 
(12 - 13%), eyelid oedema, angio-oedema, pleural/pericardial effu-
sions and lymphoedema.[6] Bilateral limb oedema is commonly 
associated with mTOR inhibitors, more commonly in patients on 
sirolimus than in those on evarolimus,[7] but the recent literature has 
indicated an increase in lymphoedema related to the drug, which 
is often permanently disfiguring.[8-10] According to previous case 
reports, it occurs between 7 months and 2 years on treatment and 
does not have a gender predisposition.[9]
Various mechanisms for the development of lymphatic obstruction 
in patients on sirolimus have been proposed. Most theories arise 
from the fact that mTOR is a downstream signal in the vascular 
endothelial growth factor pathway that mediates lymphatic survival, 
proliferation and passage. As a result, inhibition of the kinase disrupts 
lymphangiogenesis.[11]
Making the decision to stop treatment with sirolimus in our patient 
was challenging. Owing to the cost of drugs and problems with 
reliable supply, the treating facility did not have many options, and 
the patient also had good, stable graft function on sirolimus. However, 
his painful and disfiguring lymphoedema was affecting his quality of 
life. In view of his past history of calcineurin toxicity, the decision to 
change immunosuppressants could not be made lightly because of the 
possibility that his graft function would be compromised. Nonetheless, 
we needed to consider the psychological effect of his deformity and 
the effect it might have on compliance with treatment. Non-adherence 
would ultimately also have resulted in graft failure.
The patient’s lymphoedema partially subsided after sirolimus was 
discontinued. His graft function remains stable on tacrolimus, MMF 
and prednisone.
This case highlights the importance of early recognition of drug 
complications, which may prevent permanent disfiguration and 
discomfort. However, in a resource-limited environment where 
treatment options are few, drugs are expensive and drug supply is 
sometimes unreliable, clinicians may be faced with the difficult task 
of deciding between the lesser of two evils – cessation of life-saving 
treatment, and irreversible deformities.
Conclusion
Lymphoedema is a rare complication of sirolimus, and the mechan-
isms are not completely understood. However, early recognition can 
prevent permanent disfiguration. This case highlights the need for 
early recognition of adverse drug effects and further research into 
their pathophysiology and management.
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